- cafead Oct 24, 2022 at 11:12: PM
via Regeneron and Bayer’s blockbuster eye drug Eylea has been given six months more protection from competition — now extending into the first half of 2024.
The FDA granted the blockbuster VEGF inhibitor pediatric exclusivity for the next six months on Friday — sending the timeline for biosimilar market entry to May 17, 2024. Exclusivity for Regeneron’s injection was supposed to run out in late 2023.
article source
The FDA granted the blockbuster VEGF inhibitor pediatric exclusivity for the next six months on Friday — sending the timeline for biosimilar market entry to May 17, 2024. Exclusivity for Regeneron’s injection was supposed to run out in late 2023.
article source